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Abstract
PedGenie beta version 2.1 is a unique, flexible, and easily implemented analysis software tool that
is enhanced significantly by incorporation of meta-statistics to allow valid combined analysis of
multiple studies, including mixtures of family-based and independent resources, in the detection of
genetic association with common disease. Genetic Analysis Workshop 15 Problem 2 data, provided
by the North American Rheumatoid Arthritis Consortium, were used to demonstrate PedGenie
2.1 meta-association testing of variants in the PTPN22 gene and rheumatoid arthritis across multiple
resources containing both family-based and independent individuals. Our findings are generally
consistent with previous reports for a panel of 14 single-nucleotide polymorphism (SNP) markers,
including functional coding SNP R620W, in which the minor allele conferred a significant two-fold
increased risk. More power to detect associations was achieved in certain analyses by using extra
family-based samples, rather than restricting analyses to single cases randomly selected from each
pedigree.
Background
In the study of common diseases and genes with modest
effects, large consortium and multicenter efforts hold the
promise of increased power to detect associations, but
also present analytical challenges. Candidate gene study
populations differ geographically and ethnically, and con-
siderable differences in case-control ascertainment and
pedigree structures between resources are likely. Cur-
rently, no software package exists that allows valid meta-
genetic association testing in mixtures of independent and
family-based resources (including pedigrees of arbitrary
length and configuration) between or within studies.
PedGenie 2.1 (beta version) extends the functionality cur-
rently available in PedGenie (version 1.2) [1,2] by incor-
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porating meta-statistics for combined analysis of
multistudy resources, along with Monte Carlo signifi-
cance testing, which allows for a mixture of pedigree
members (both nuclear and extended families) and inde-
pendent individuals. Data from Problem 2 of the Genetic
Analysis Workshop 15 (GAW15) were used to demon-
strate meta-association testing of the PTPN22 candidate
gene (14 single-nucleotide polymorphisms, or SNPs) and
consensus criteria rheumatoid arthritis (RA) phenotype
and sub-phenotypes in combined family-based and inde-
pendent individuals using PedGenie 2.1. RA, a common
systemic autoimmune disease, affects about 1% of adults
worldwide and has an estimated heritability of 50 to 60%
[3,4]. The association of RA susceptibility with a missense
variant in the hematopoietic-specific protein tyrosine
phosphatase gene, PTPN22  (R620W, rs2476601), has
been previously suggested [3].
Methods
PTPN22 SNP and RA phenotype data
Data provided by the North American Rheumatoid Arthri-
tis Consortium (NARAC) were obtained for 14 SNPs in
PTPN22. The genotypes and phenotypes were collected
from Caucasian individuals in NARAC affected sibling-
pair families (1393 cases) and 1519 matched, independ-
ent non-diseased controls from New York City (NYC),
reported in Carlton et al. [5]. Within this sample were data
for 839 affected sib-pair cases and 855 controls, reported
in Plenge et al. [6]. In addition to RA status (affected or
unaffected), detailed phenotype information available on
most cases included rheumatoid factor IgM (RF), a meas-
ure of active disease correlated with erosive arthritis. A
threshold of 11 and greater was designated as RF+. In
Kroot et al. [7] RF titers under 10 were considered normal;
however, as levels below 11 could not be quantitated
accurately, we used this slightly higher threshold. Elevated
anti-cyclic citrullinated peptide (anti-CCP) levels have
been shown to predict increased risk for RA development,
with an antibody titer threshold of 49 or greater consid-
ered anti-CCP+ [4].
Demonstration studies: NARAC 1 and NARAC 2
For the purpose of demonstrating meta-analysis across
multiple studies with PedGenie 2.1 in association testing
of a candidate gene, the PTPN22 SNP and phenotype data
were separated into two study files, designated NARAC 1
and NARAC 2 (Table 1). NARAC 2 comprised the 1694
individuals that were studied by Plenge et al. [6], includ-
ing both families and independent controls. NARAC 1
comprised all remaining individuals, family cases, unaf-
fected family controls, and independent NYC controls.
Because PedGenie can incorporate family relationships in
association testing, any individuals were included for
whom affected status could be determined and genotypes
were available. Specifically, the data analyzed contained
siblings and genotyped parents. In two NARAC 1 pedi-
grees, four adult offspring in affected sibships with geno-
types and RA diagnosis between ages 17 to 44 were also
available. Including unaffected siblings with genotypes
resulted in an additional 103 family-based controls for
analysis in NARAC 1.
PedGenie 2.1
Use of family data for allelic or genotype association test-
ing must account for correlations between related individ-
uals to avoid underestimation of variance in a statistic of
interest and increased type I error. Several family-based
association methods exist, but most are limited by pedi-
gree structure or the statistics that can be performed. Ide-
ally, utilizing all available information on pedigree
Table 1: PTPN22 SNP data: study descriptives
NARAC Study 1a NARAC Study 2a
C a s e sC o n t r o l sC a s e s C o n t r o l s
N % N % N % N %
RA 446 767 839 854
Family-based 446 100.0 103 13.4 839 100.0 -- --
Independent -- -- 664 86.6 -- -- 854 100.0
Age at onsetb 39 13.9 -- -- 39 13.1 -- --
RF+ (≥ 11) 346 77.5 -- -- 708 84.4 -- --
RF- (< 11) 89 20.0 -- -- 129 15.4 -- --
RF unknown 11 2.5 -- -- 2 0.2 -- --
anti-CCP+ (≥ 49) 267 59.9 -- -- 545 65.0 -- --
anti-CCP- (< 49) 141 31.6 -- -- 274 32.7 -- --
anti-CCP unknown 38 8.5 -- -- 20 2.4 -- --
aStudy 1: 202 pedigrees with genotypes; Study 2: 463 pedigrees with genotypes.
bMedianBMC Proceedings 2007, 1(Suppl 1):S12 http://www.biomedcentral.com/1753-6561/1/S1/S12
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structure is the most informative approach [1], and, for
multi-group efforts, the availability of meta-statistics.
PedGenie 2.1, which is a Monte Carlo based method, has
been developed with meta-capabilities, which entails the
use of study-specific allele or haplotype frequencies and
established meta-statistics [8]. Briefly, the Monte Carlo
procedure is based on simulating null genotype configu-
rations for each resource and deriving null meta-statistics
across resources, achieved as follows. Alleles are estimated
within each resource. Alleles are then assigned to founders
randomly, in proportion to estimated allele frequencies
for the specific resource and a Mendelian gene-drop sim-
ulation is performed independent of phenotype; each
possible null genotype configuration is used to calculate a
null meta-statistic. This is repeated to create an empirical
null distribution for significance testing. PedGenie, freely
available and easily implemented in a computing envi-
ronment running Java 1.5 [1], was developed to allow
flexibility in hypothesis testing; tests may be constructed
for alleles or genotypes in any user-defined grouping,
using any reference group as baseline. Several options are
available within PedGenie to estimate allele frequencies
for the gene-drops. In the NARAC 1 and NARAC 2
resources, there are a large number of relatively small ped-
igrees and the number of genotyped founders is limited.
Therefore, the allele frequencies were estimated from all
genotyped individuals. The empirical null distributions
were created from 1000 simulations. PedGenie appropri-
ately handles sparse data and missing data structure [1].
By providing information on the number of simulations
for which a statistic can be calculated, sparse data is indi-
cated when the number of simulations in which a statistic
is calculated is less than the total number of simulations.
In the gene drop procedure, individuals missing geno-
types for a specific locus are reset to missing, and calcula-
tion of test statistics in the simulated data are limited to
individuals with observed genotypes [1].
Meta-statistics
PedGenie beta version 2.1 incorporates meta-statistics to
allow valid combined analysis of multiple studies, includ-
ing family-based resources, in the detection of genetic
association with common disease. In epidemiologic stud-
ies, data are often collected that can be summarized in
three-way contingency tables, the presence or absence of a
disease phenotype cross-classified with allele or genotype
and a controlling for a third categorical variable (study)
which represents combinations of levels of several varia-
bles (race, sex, age, etc.) [9]. Meta statistics for genotype,
composite genotype, or haplotype analysis across studies
currently incorporated in PedGenie 2.1 are based on the
generalized Cochran-Mantel-Haenszel (CMH) approach
described elsewhere [8,10]. CMH procedures are used to
calculate odds ratios, chi-squared general association test
of independence, and chi-squared test of trend (mean
score statistic where ordered wild-type, heterozygous, and
homozygous variant genotypes lie on an ordinal scale).
Results
The study characteristics and RA phenotypes used to dem-
onstrate PedGenie 2.1 meta-association analysis are
described in Table 1. Allele frequencies for controls and
PTPN22 SNP associations with RA for each demonstration
study and the combined study PedGenie 2.1 meta-analy-
sis results are shown in Table 2, along with previously
published reports. Generally, our meta-analysis results
using GAW15 data corroborate previous findings for the
panel of 14 SNP markers that includes functional coding
SNP R620W [5,6]. It is of note that on inspection of link-
age disequilibrium (LD) between SNPs, R620W was not
in strong pairwise LD with any other SNP in the set. Mark-
ers rs1217413, rs1217388, rs1310182, and rs1217414
were in pairwise LD (measured by r2 > 0.4) with each
other. SNPs rs12730735 and rs12760457 were in com-
plete LD. SNP ss38346943, which has a rare, protective
minor allele, was not in LD with any other marker.
Table 3 shows genotype associations with RA and PTPN22
markers for an additive model (Armitage test for trend
[11]) that were significant in at least one study. Previ-
ously, Carlton et al. reported two markers with associa-
tions independent of R620W; rs3789604 and rs1310182,
both in putative transcription factor binding sites [5]. The
odds ratios reported by Carlton et al. were adjusted
accordingly, and these are shown in Table 3. R620W was
adjusted for rs3789604, and rs3789604 and rs1310182
were adjusted for R620W.
Previous studies reported that susceptible PTPN22 R620W
genotypes containing the variant allele were strongly asso-
ciated with RF+ but not RF- disease [3,6]. Our meta-anal-
ysis supported an association in RF+ cases only compared
to controls, although a comparison of RF+ to RF- cases
was not significant (Table 4). Plenge et al. reported an
association with R620W variant genotypes and anti-CCP+
cases, but not in anti-CCP- cases [6]. Our meta-analysis
showed an association for anti-CCP+ cases and anti-CCP-
cases in comparison to controls (Table 4). Thus, in our
larger meta-analysis across studies, we could not confirm
that anti-CCP level discriminates in R620W-associated
RA. However, an association was seen for SNPs in pairwise
LD (rs1217413, rs1217388, rs1310182, and rs2488458)
and anti-CCP+ cases only vs. controls (heterozygous/vari-
ant vs. wild-type odds ratios (ORs) between 1.4 and 1.5,
95% confidence interval (CI), 1.2 to 1.8). Further, the
comparison of anti-CCP+ to anti-CCP- cases was signifi-
cant for these markers.BMC Proceedings 2007, 1(Suppl 1):S12 http://www.biomedcentral.com/1753-6561/1/S1/S12
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Discussion
PedGenie 2.1 can correct for all relationships in family-
based resources, therefore all family members with phe-
notype and genotype data are available can be included. If
only one affected sibling was chosen from each pedigree,
the sample size here would have reduced from 1285 cases
and 1621 controls to 665 and 1518, respectively. For
example, in NARAC 1, a family with five affected and five
unaffected genotyped siblings and parents with known RA
status (one genotyped) were included in PedGenie analy-
ses, whereas only one affected sib was randomly selected
from this family for the study performed by Carlton et al.
[5].
CMH statistics for ordered genotypes have been used to
assess association in multiple case-control studies in
which cases are independent, either probands or ran-
domly selected affecteds [12]. A combined odds ratio esti-
mate of the association in both case-control and
transmission-disequilibrium studies have been proposed
[13]. PedGenie beta 2.1 allows for valid meta-analyses of
combined family-based and case-control studies using
CMH techniques, while accommodating comprehensive
information in large, multigenerational families without
pedigree splitting required in other packages. The ability
to combine family and case-control resources and use all
data available both increases the utility of prior linkage
resources and can provide increased power to detect asso-
ciations, particularly in stratified and subset analyses that
likely lead to small sample sizes in individual studies.
In conclusion, our method is a more comprehensive way
of using all data available in meta-association testing,
with more power to detect associations by using extra
family-based samples rather than restricting to randomly
selected cases from each pedigree. Our findings generally
corroborate those previously reported. We support previ-
ous findings that the PTPN22 gene is associated with RA.
However, our results do not indicate that anti-CCP anti-
body status significantly discriminates for disease in the
functional R620W SNP.
Competing interests
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Table 2: Allele-based associations with RA (case-control comparison, odds ratios (ORs) estimated for minor allele)
PedGenie 2.1
NARAC Study 1a NARAC Study 2b Meta-analysis Previously publishedc,d
PTPN22 MAFe OR 95% CI pf MAFe OR 95% CI pf OR 95% CI pg OR 95% CI ph
Rs3789604 0.182 1.11 0.88–1.41 0.36 0.175 1.15 0.95–1.39 0.17 1.13 0.98–1.32 0.10 1.15 0.97–1.35 0.11
Rs3811021 0.182 1.11 0.88–1.40 0.38 0.176 1.14 0.95–1.37 0.17 1.13 0.97–1.31 0.11 1.15 0.97–1.36 0.10
rs1217413 0.210 1.38 1.13–1.70 0.003 0.230 1.28 1.07–1.53 0.002 1.32 1.16–1.51 <0.001 1.37 1.18–1.60 <0.001
ss38346942 0.015 1.21 0.61–2.37 0.59 0.012 1.22 0.65–2.27 0.56 1.21 0.75–1.97 0.42 1.03 0.59–1.79 1.00
rs1217388 0.246 1.29 1.04–1.59 0.017 0.260 1.20 1.01–1.42 0.028 1.23 1.07–1.42 0.003 1.28 1.11–1.49 0.001
ss38346943 0.031 0.32 0.16–0.67 0.001 0.023 0.84 0.47–1.48 0.55 0.60 0.39–0.92 0.020 0.63 0.40–1.01 0.05
rs1310182 0.430 1.28 1.06–1.56 0.008 0.435 1.28 1.09–1.49 0.001 1.28 1.13–1.45 <0.001 1.35 1.18–1.54 <0.001
ss38346944 0.029 1.14 0.65–1.99 0.63 0.019 1.37 0.84–2.22 0.24 1.26 0.85–1.85 0.24 1.29 0.87–1.93 0.21
rs2476601 0.087 1.79 1.39–2.30 <0.001 0.085 2.19 1.75–2.74 <0.001 2.03 1.70–2.42 <0.001 1.93 1.58–2.37 <0.001
(R620W) 2.184 1.76–2.70 <0.001
rs12730735 0.292 0.83 0.68–1.01 0.07 0.295 0.89 0.76–1.04 0.14 0.86 0.76–0.98 0.025 0.81 0.70–0.94 0.006
rs11102685 0.076 1.21 0.87–1.77 0.26 0.078 1.20 0.93–1.55 0.19 1.20 0.98–1.49 0.09 1.27 1.01–1.60 0.040
rs12760457 0.291 0.83 0.68–1.02 0.09 0.296 0.88 0.74–1.05 0.14 0.86 0.76–0.98 0.022 0.82 0.71–0.96 0.010
rs2488458 0.246 1.29 1.05–1.58 0.014 0.260 1.20 1.01–1.41 0.037 1.23 1.08–1.41 0.003 1.27 1.10–1.48 0.002
rs1217414 0.282 0.88 0.70–1.10 0.20 0.270 0.84 0.72–0.99 0.06 0.86 0.76–0.97 0.018 0.84 0.72–0.98 0.020
aProblem 2, 446 family cases and 103 family controls in 202 NARAC pedigrees, 664 independent NYC controls; excludes Plenge et al. [6] samples.
bProblem 2, samples in Plenge et al. [6] candidate gene file, 839 family cases in 463 pedigrees and 854 independent NYC controls.
cCarlton et al. [5] sample set 2 (661 randomly selected independent cases from NARAC pedigrees and 1322 independent NYC controls).
dPlenge et al. [6] second collection; 840 family cases (NARAC) and 867 independent NYC controls: R620W SNP only.
eMinor allele frequency in controls.
fEmpirical confidence intervals and chi-square p-values, 1000 simulations; p < 0.05 in bold.
gEmpirical confidence intervals and CMH chi-square general association test, 1000 simulations; p < 0.05 in bold.
hFisher's exact chi-square test; p < 0.05 in bold.BMC Proceedings 2007, 1(Suppl 1):S12 http://www.biomedcentral.com/1753-6561/1/S1/S12
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Table 3: Genotype-based associations with RA (case-control comparison, reference is major allele homozygote)
PedGenie 2.1
NARAC Study 1a NARAC Study 2b Meta-analysis Previously publishedc
PTPN22 Genotyped OR 95% CI p-trende OR 95% CI p-trende OR 95% CI p-trendf OR 95% CI p-trend
rs3789604 AC 0.94 0.69–1.26 1.16 0.93–1.46 1.07 0.91–1.26 1.15 0.93–1.42
CC 1.68 0.83–3.38 0.39 1.25 0.70–2.21 0.18 1.43 0.93–2.18 0.12 1.78 1.13–2.79 0.014
rs1217413 TC 1.44 1.11–1.87 1.34 1.08–1.66 1.38 1.17–1.63
CC 1.71 1.06–2.75 0.003 1.52 1.00–2.31 0.002 1.59 1.14–2.22 <0.001
rs1217388 TC 1.49 1.14–1.93 1.30 1.05–1.61 1.37 1.15–1.63
CC 1.30 0.78–2.17 0.017 1.27 0.86–1.87 0.026 1.28 0.94–1.74 0.003
ss38346943 TC 0.32 0.15–0.69 0.88 0.48–1.61 0.61 0.39–0.95
CC -- -- -- -- -- -- -- -- --
rs1310182 CT 1.55 1.13–2.13 1.39 1.11–1.73 1.45 1.20–1.75 1.22 0.98–1.77
TT 1.57 1.07–2.30 0.011 1.62 1.18–2.22 <0.01 1.60 1.25–2.03 <0.001 1.32 0.97–1.54 0.052
rs2476601 CT 1.92 1.41–2.60 2.36 1.84–3.04 2.18 1.80–2.65 2.19 1.73–2.78
(R620W) TT 1.96 0.74–5.21 <0.001 2.91 1.26–6.74 <0.001 2.53 1.32–4.84 <0.001 2.90 1.37–6.18 <0.001
rs12730735 AG 1.00 0.75–1.31 1.10 0.89–1.36 1.06 0.89–1.25
GG 0.48 0.29–0.80 0.08 0.56 0.37–0.83 0.14 0.53 0.39–0.72 0.024
rs12760457 AG 1.01 0.75–1.36 1.09 0.87–1.37 1.06 0.89–1.26
GG 0.48 0.28–0.82 0.09 0.55 0.37–0.82 0.14 0.52 0.38–0.72 0.023
rs2488458 GA 1.51 1.15–1.97 1.33 1.07–1.66 1.40 1.18–1.67
AA 1.27 0.79–2.05 0.014 1.20 0.81–1.78 0.037 1.23 0.91–1.67 0.003
rs1217414 CT 1.02 0.77–1.35 0.85 0.69–1.04 0.91 0.78–1.06
TT 0.60 0.34–1.03 0.20 0.70 0.46–1.06 0.053 0.65 0.46–0.92 0.018
aProblem 2 data, 446 family cases and 103 family controls in 202 affected NARAC pedigrees, 664 independent NYC controls; excludes Plenge et al. 
[6] samples.
bProblem 2 data, samples in Plenge et al. [6] candidate gene file, 839 family cases in 463 pedigrees and 854 independent NYC controls.
cCarlton et al. [5] sample set 2, 661 random independent cases from NARAC pedigrees and 1322 NYC controls; adjusted for R620W or 
rs3789604 (R620W).
dMinor allele heterozygote and homozygote genotypes according to Carlton et al. [5] Table 1.
eEmpirical confidence intervals and chi-square p-values, 1000 simulations; p < 0.05 in bold.
fEmpirical confidence intervals and CMH chi-square trend test p-values, 1000 simulations; p < 0.05 in bold.
Table 4: Genotype-based associations with R620W and RA sub-type (reference is major allele CC homozygote)
PedGenie 2.1
NARAC Study 1a NARAC Study 2b Meta-analysis Previously publishedc
RA Phenotype Genotype OR 95% CI pd OR 95% CI pd OR 95% CI pe OR 95% CI p
RF+ vs. Ctrls. CT or TT 1.80 1.29–2.49 <0.001 2.34 1.82–3.00 <0.001 2.13 1.76–2.57 <0.001 2.36 1.76–3.16 <0.001
RF- vs. Ctrls. CT or TT 1.40 0.87–2.27 0.20 1.08 0.71–1.65 0.77 1.20 0.87–1.65 0.31 1.17 0.6–2.31 0.64
RF+ vs. RF- CT or TT 1.07 0.58–2.00 0.79 1.46 0.83–2.56 0.12 1.30 0.86–1.95 0.18
Previously publishedf
CCP+ vs. Ctrls. CT or TT 1.69 1.18–2.41 0.001 2.03 1.57–2.62 <0.001 1.90 1.55–2.34 <0.001 1.49 1.23–1.79 <0.001
CCP- vs. Ctrls. CT or TT 1.59 1.04–2.45 0.035 1.41 1.03–1.95 0.029 1.47 1.15–1.88 0.001 1.04 0.83–1.29 0.40
CCP+ vs. CCP- CT or TT 1.05 0.61–1.80 0.93 1.16 0.83–1.60 0.32 1.12 0.84–1.50 0.47
RF or CCP+ 
vs. RF-/CCP-
CT or TT 1.29 0.65–2.53 0.55 1.43 0.81–2.52 0.06 1.38 0.89–2.13 0.051 1.43 1.16–1.77 <0.001
aProblem 2 data, 446 family cases and 103 family controls in 202 affected NARAC pedigrees, 664 independent NYC controls; excludes Plenge et al. 
[6] samples.
bProblem 2 data, samples in Plenge et al. [6] candidate gene file, 839 family cases in 463 pedigrees and 854 independent NYC controls.
cBegovich et al. [3] replication sample (NARAC; 463 independent-sib cases, 926 independent controls), CLR analysis.
dEmpirical confidence intervals and chi-square p-values, 1000 simulations; p < 0.05 in bold.
eEmpirical confidence intervals and CMH chi-square general association test, 1000 simulations; p < 0.05 in bold.
fPlenge et al. [6] first clinical collection, Epidemiological Investigation of RA (EIRA) Swedish cohort (2370 cases 1757 controls); allele association.Publish with BioMed Central    and   every 
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